Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms
With Concentra Biosciences expanding its stock influence on Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition.
With Concentra Biosciences expanding its stock influence on Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition.
